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formerly known as anti-p155), which has been 
shown to be useful in the diagnosis of cancer-
associated myositis.2,3 In the reported case, 
negativity for this antibody would imply that the 
improvement in dermatomyositis was due to 
the administration of ruxolitinib rather than to 
the improvement in the hematologic cancer. We 
think that such a determination would help in 
better understanding the excellent response to 
this drug.
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The authors reply: Dermatomyositis is known 
to be associated with cancers in approximately 
25% of patients with the condition. However, 
dermatomyositis occurring in the course of myelo-
fibrosis is extremely rare. Anti-TIF1γ antibodies 
have been linked to paraneoplastic dermatomyo-
sitis, but their clinical significance is still contro-
versial, and the antibody level is not routinely 
measured.1
In our patient, we believe that the dramatic 
and rapid clinical effects were due to the anti-
inflammatory properties of the Janus kinase 
(JAK) inhibitor, even though we cannot rule out 
the possibility that myelofibrosis-induced in-
flammation triggering dermatomyositis also 
might have been inhibited. Ruxolitinib induces 
only very limited activity against the JAK2-mutat-
ed clone, and its therapeutic effects in myelofi-
brosis are not determined by the patient’s JAK2 
mutational status, which supports the idea that 
clinical improvement is not due to a reduction in 
the tumor burden.2 Thus, inhibition of the pro-
duction or secretion of cutaneous proinflamma-
tory key cytokines (CXCL9 and CXCL10) appears 
to be the predominant therapeutic effect of the 
drug.3 This idea is further supported by the po-
tent antiinflammatory capacity of ruxolitinib in 
graft-versus-host disease, a disorder in which the 
histologic and immunologic patterns show strik-
ing similarities to those of dermatomyositis.4,5
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Ebola	Virus	Disease	among	Children	in	West	Africa
To the Editor: The epidemic of Ebola virus dis-
ease (EVD) in West Africa has caused clinical ill-
ness and deaths among persons with reported 
ages ranging from less than 1 year to more than 
100 years. Most published estimates of key epide-
miologic parameters have been based on patients 
of all ages1,2 and have thus been dominated by 
cases in which patients are 16 years of age or 
older, and as of January 5, 2015, these cases ac-
counted for 79% of the confirmed and probable 
cases for which age has been reported.
Here we investigate the progression and out-
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come of EVD in confirmed and probable pediatric 
cases reported from Guinea, Liberia, and Sierra 
Leone, stratified according to age. The absolute 
and per capita case incidence of EVD among 
children younger than 16 years of age has been 
significantly and consistently lower than the 
incidence among adults in all three countries 
(Fig. 1A, 1B, and 1C). This pattern is similar to 
that observed in past EVD outbreaks.3,4 However, 
because the current epidemic is so large, it pro-
vides an opportunity to explore the ways in 
which epidemiologic and clinical parameters vary 
according to age. Although the age distribution 
of confirmed, probable, and suspected cases is 
similar in all three countries (Fig. S3 in the 
Supplementary Appendix, available with the full 
text of this letter at NEJM.org), the proportion of 
pediatric cases (those younger than 16 years of 
age) among all cases increased over the course 
of 2014 (Fig. 1C, and Fig. S4 in the Supplemen-
tary Appendix).
The mean incubation period (the average time 
from infection until symptom onset) was short-
est, on average, in the youngest children, with 
means ranging from 6.9 days (95% confidence 
interval [CI], 5.1 to 9.5) in 14 children younger 
than 1 year of age to 9.8 days (95% CI, 8.7 to 
11.1) in 184 children 10 to 15 years of age (Fig. 
1D, and Table S1 and Fig. S5 in the Supplemen-
tary Appendix). Younger children also had short-
er times from symptom onset to hospitalization 
and from symptom onset to death (Fig. 1D, and 
Fig. S6 and S7 and Tables S2 and S3 in the 
Supplementary Appendix). There was no clear 
evidence that age affected the distribution of the 
intervals between symptom onset and hospital 
discharge, between hospitalization and death, 
between hospitalization and hospital discharge, 
or between symptom onset and onward trans-
mission (Fig. S8 to S11 and Tables S4 to S7 in 
the Supplementary Appendix).
Almost all children with EVD who were 
younger than 1 year of age had fever (92%) be-
fore clinical presentation, and children younger 
than 16 years of age were more likely than adults 
to present with fever (P<0.001) (Table S8 and Fig. 
S13 in the Supplementary Appendix). Children 
were less likely than adults (i.e., persons 16 years 
of age or older) to report pain in the abdomen, 
chest, joints, or muscles, difficulty breathing or 
swallowing, and hiccups between symptom on-
set and clinical presentation (P<0.001); however, 
this finding may reflect the difficulty young 
children have in reporting such symptoms rather 
than a different symptom profile (Table S8 and 
Fig. S12 in the Supplementary Appendix). The 
case fatality rate (CFR) was lowest among chil-
dren between 10 and 15 years of age and highest 
among those 4 years of age or younger (Fig. 1E, 
and Fig. S14 and S15 and Table S9 in the Supple-
mentary Appendix). The CFR for persons young-
er than 45 years of age (most of whom are 5 to 
44 years of age) was lower than that among 
those 45 years of age or older (Fig. 1E), a finding 
that is in line with that of an earlier report.5
The shorter incubation period in children, the 
relatively high risk of death among children 
younger than 5 years of age (as compared with 
older children), and the more rapid progression 
to death highlight the importance of including 
children among case contacts for follow-up, of 
examining children for early signs of disease 
during active case finding, and of explaining the 
risk of EVD to parents, guardians, and caregiv-
ers. All persons in whom EVD is suspected, but 
especially children, need the earliest possible 
referral for diagnostic testing, and children need 
age-appropriate treatment. The causes of the 
Figure	1	(next	page).	Age-Group–Specific	Incidence	of	Ebola	Virus	Disease	in	West	Africa,	Incubation	Period,	Inter-
vals	from	Onset	to	Death	and	Onset	to	Hospitalization,	and	Case	Fatality	Rate.
Panel A shows the cumulative incidence of confirmed and probable cases of Ebola virus disease (EVD) according to 
age group and country. Panel B shows the cumulative incidence of confirmed and probable cases per 10,000 popula-
tion according to age group and country. Panel C shows the overall age distribution for confirmed and probable cases 
according to month of symptom onset. Panel D shows the estimated average incubation period, the interval be-
tween symptom onset and death, and the interval between symptom onset and hospitalization according to age 
among persons with confirmed or probable EVD (with vertical lines indicating 95% confidence intervals [CIs]). The 
numbers represent the sample sizes in each age group. Panel E shows the estimated case fatality rate according to age 
among persons with confirmed or probable EVD (with 95% CIs), with representation of the total number of con-
firmed or probable cases of EVD cases in each age group and the total number of confirmed or probable cases of 
EVD for which there was information on the final outcome in each age group. 
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notices
relatively rapid disease progression and relatively 
high CFR in the youngest children requires fur-
ther investigation.
WHO Ebola Response Team
The authors (members of the WHO Ebola Response Team 
who contributed to this letter, in alphabetic order) are as follows: 
Junerlyn Agua-Agum, M.P.H., Archchun Ariyarajah, M.Sc., Iso-
bel M. Blake, Ph.D., Anne Cori, Ph.D., Christl A. Donnelly, 
Sc.D., Ilaria Dorigatti, Ph.D., Christopher Dye, D.Phil., Tim Eck-
manns, M.D., Neil M. Ferguson, D.Phil., Robert A. Fowler, M.D. 
C.M. M.S (Epi)., Christophe Fraser, Ph.D., Tini Garske, Ph.D., 
Wes Hinsley, Ph.D., Thibaut Jombart, Ph.D., Harriet L. Mills, 
Ph.D., Srinivas Murthy, M.D. C.M., Gemma Nedjati‐Gilani, 
Ph.D., Pierre Nouvellet, Ph.D., Louise Pelletier, M.D., Steven Ri-
ley, D.Phil., Dirk Schumacher, M.Sc., Anita Shah, M.Sc., Maria D. 
Van Kerkhove, Ph.D.
The authors’ affiliations are as follows: World Health Organi-
zation (WHO), Geneva (J.A.-A., A.A., C.D., T.E., L.P., D.S., A.S.); 
Department of Medicine and Department of Critical Care Medi-
cine, Sunnybrook Hospital, Interdepartmental Division of Criti-
cal Care Medicine, University of Toronto (R.A.F.); Department of 
Pediatrics, University of British Columbia (S.M.); The Medical 
Research Council Centre for Outbreak Analysis and Modelling, 
WHO Collaborating Centre for Infectious Disease Modelling, 
Department of Infectious Disease Epidemiology, Imperial Col-
lege London, United Kingdom (I.M.B., A.C., C.A.D., I.D., 
N.M.F., C.F., T.G., W.H., T.J., H.L.M., G.N.‐G., P.N., S.R., 
M.D.V.K.); Robert Koch Institute, Department for Infectious 
Disease Epidemiology, Berlin, Germany (T.E., D.S.).
Address reprint requests to Dr. Donnelly (c.donnelly@imperial 
 .ac.uk), Dr. Dye (dyec@who.int), or Dr. Ferguson (neil.ferguson@
imperial.ac.uk).
The study was conducted in support of the response to the 
Ebola outbreak in Guinea, Liberia, and Sierra Leone and is based 
on data routinely collected by national and international staff in 
conjunction with WHO. 
Supported by the Medical Research Council, the Bill and Me-
linda Gates Foundation, the Models of Infectious Disease Agent 
Study of the National Institute of General Medical Sciences, Na-
tional Institutes of Health, the Health Protection Research Units 
of the National Institute for Health Research, the European 
Union PREDEMICS consortium, the Wellcome Trust, and Fog-
arty International Center. Disclosure forms provided by the au-
thors are available with the full text of this letter at NEJM.org.
1.	 WHO Ebola Response Team. Ebola virus disease in West 
Africa — the first 9 months of the epidemic and forward projec-
tions. N Engl J Med 2014;371:1481-95.
2.	 WHO Ebola Response Team. West African Ebola epidemic 
after one year — slowing but not yet under control. N Engl J Med 
2015;372:584-7.
3.	 Outbreak of Ebola haemorrhagic fever, Uganda, August 
2000–January 2001. Wkly Epidemiol Rec 2001;76:41-6.
4.	 Mupere E, Kaducu OF, Yoti Z. Ebola haemorrhagic fever 
among hospitalised children and adolescents in northern Ugan-
da: epidemiologic and clinical observations. Afr Health Sci 2001; 
1:60-5.
5.	 Bah EI, Lamah M-C, Fletcher T, et al. Clinical presentation 
of patients with Ebola virus disease in Conakry, Guinea. N Engl 
J Med 2015;372:40-7.
DOI:	10.1056/NEJMc1415318	
Correspondence Copyright © 2015 Massachusetts Medical Society.
instructions for letters to the editor
Letters	to	the	Editor	are	considered	for	publication,	subject	
to	 editing	 and	 abridgment,	 provided	 they	 do	 not	 contain	
material	 that	 has	 been	 submitted	 or	 published	 elsewhere.	
Please	note	the	following:
•	 Letters	in	reference	to	a	Journal	article	must	not	exceed	175	
words	(excluding	references)	and	must	be	received	within	
3	weeks	after	publication	of	the	article.
•	 Letters	not	related	to	a	Journal	article	must	not	exceed	400	
words.
•	 A	letter	can	have	no	more	than	five	references	and	one	figure	
or	table.
•	 A	letter	can	be	signed	by	no	more	than	three	authors.
•	 Financial	associations	or	other	possible	conflicts	of	interest	
must	be	disclosed.	Disclosures	will	be	published	with	the	
letters.	(For	authors	of	Journal	articles	who	are	responding	
to	letters,	we	will	only	publish	new	relevant	relationships	
that	have	developed	since	publication	of	the	article.)
•	 Include	your	full	mailing	address,	 telephone	number,	 fax	
number,	and	e-mail	address	with	your	letter.
•	 All	letters	must	be	submitted	at	authors.NEJM.org.
Letters	that	do	not	adhere	to	these	instructions	will	not	be	
considered.	We	will	notify	you	when	we	have	made	a	decision	
about	possible	publication.	Letters	regarding	a	recent	Journal	
article	may	be	shared	with	the	authors	of	that	article.	We	are	
unable	 to	 provide	 prepublication	 proofs.	 Submission	 of	 a	
letter	constitutes	permission	for	the	Massachusetts	Medical	
Society,	its	licensees,	and	its	assignees	to	use	it	in	the	Journal’s	
various	print	and	electronic	publications	and	in	collections,	
revisions,	and	any	other	form	or	medium.
notices
Notices submitted for publication should contain a mailing 
address and telephone number of a contact person or depart-
ment. We regret that we are unable to publish all notices 
 received. Notices also appear on the Journal’s website 
(NEJM.org/medical-conference). The listings can be viewed 
in their entirety or filtered by specialty, location, or month.
GYN SurGErY WEEk 2015
The conference will be held in Fort Lauderdale, FL, April 15–18. 
It is presented by the Cleveland Clinic Women’s Health Institute.
Contact Cleveland Clinic Center for Continuing Education, 
3050 Science Park Dr., AC313, Beachwood, Ohio 44122; or call 
(954) 659-5490; or e-mail cmeregistration@ccf.org; or see 
http://www.ccfcme.org/GYNSurgWeek.
Survival SkillS for TodaY’S GYNEcoloGiST 2015
The annual meeting will be held in New York, April 17–19.
Contact World Class CME, 6201 Fairview Rd., Suite 322, 
Charlotte, NC 28210; or call (980) 819-5095; or fax (980) 819-
5099; or email office@worldclasscme.com; or see http://www 
.worldclasscme.com/conferences/survival-skills-todays 
-gynecologist1.
EuropEaN MolEcular BioloGY laBoraTorY
The following meetings will be held in Heidelberg, Germany: 
“Mechanisms of Neurodegeneration” (June 14–17) and “Cancer 
Genomics” (Nov. 1–4).
Contact European Molecular Biology Laboratory, Course and 
Conference Office, Meyerhofstr. 1, D-69117 Heidelberg, Ger-
many; or call (49) 6221 387 8359; or fax (49) 6221 387 8158; or see 
The New England Journal of Medicine 
Downloaded from nejm.org at IMPERIAL COLLEGE LONDON on May 12, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
